Halozyme says €2 billion takeover of Evotech would create leader in drug...

Published on 18 Nov 2024 on Market Watch

Halozyme says the combined company would have an estimated $2 billion in revenue in 2025.

Read the rest of the article

Start tracking your investments with Statfolio

Investors in Halozyme Therapeutics, Inc. HALO need to pay close attention to the stock based on...

Zacks · via Yahoo Finance 9 Jan 2025

Shares of Halozyme Therapeutics, Inc. HALO were up 5% on Jan. 8 after the company raised its...

Zacks · via Yahoo Finance 9 Jan 2025

LDOS, Amazon.com, Inc. AMZN, Halozyme Therapeutics, Inc. HALO and BioMarin Pharmaceutical Inc. BM...

Zacks · via Yahoo Finance 7 Jan 2025

Halozyme Therapeutics, Inc. HALO announced that it has withdrawn its non-binding proposal to acqu...

Zacks · via Yahoo Finance 25 Nov 2024

Have a confidential tip for our reporters? Halozyme Therapeutics Inc. withdrew its bid to purchas...

Bloomberg 22 Nov 2024

Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announc...

Benzinga · via Yahoo Finance 22 Nov 2024

Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announc...

Benzinga · via AOL 22 Nov 2024

Halozyme says the combined company would have an estimated $2 billion in revenue in 2025.

Market Watch 18 Nov 2024

(Bloomberg) -- Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed...

Bloomberg · via Yahoo Finance 17 Nov 2024

On Thursday, Halozyme Therapeutics, Inc. (NASDAQ:HALO) submitted a non-binding proposal to Evotec...

Benzinga · via Yahoo Finance 15 Nov 2024